What semaglutide user reviews actually tell you — and what they miss

The biggest misconception in semaglutide reviews: that the starting dose predicts everything

Scroll through any collection of Wegovy user reviews and you will find a pattern that can be quietly misleading: people who stopped early, often on the 0.25mg or 0.5mg starting doses, reporting little effect. The doses used in the early weeks of treatment are there to help the body adjust, not to deliver the full therapeutic effect. Reviewers who judged semaglutide a failure at that stage and moved on were, in most cases, stopping before the medicine reached the doses where meaningful weight loss tends to occur.

This is not a criticism of anyone's experience. Tolerability matters, and if side effects are severe enough to stop treatment, that is a legitimate clinical reason. But it does mean that reviews clustered at low doses tell you more about early tolerance than about long-term outcomes. The weight loss results people report look quite different once users have been established on 1.7mg or 2.4mg for several months, which aligns more closely with what the STEP 1 trial found.

The STEP 1 trial, published in the New England Journal of Medicine, followed adults using semaglutide 2.4mg weekly over 68 weeks alongside lifestyle changes and reported an average body-weight reduction of around 15%. That is a trial average across a defined population, some participants lost significantly more, others less. User reviews mirror that spread.

Side effects: what reviews reflect versus what the data shows

The most consistent theme across semaglutide user reviews is GI discomfort, particularly in the first weeks. Nausea is most commonly mentioned; constipation, loose stools, indigestion and burping appear frequently too. Fatigue and headaches come up less often but are reported. Most people who stick with treatment say these effects settled, though that is partly a survivorship point, those who stopped early due to side effects are less likely to leave a follow-up review.

What reviews tend to understate is the broader side-effect picture that clinical guidance covers. The NHS semaglutide medicine page lists the full range, including less common effects and signs that need prompt medical attention. Pancreatitis is a known but infrequent risk, severe stomach pain radiating to the back should prompt urgent medical review. For anyone reading Wegovy side effect accounts online, the NHS resource is a more reliable guide to the complete picture than review threads alone.

One thing reviews consistently do capture well: the emotional dimension. Many people describe relief at finding appetite genuinely quieter than it has been for years. Others describe frustration when the effect plateaus or when a missed dose brings appetite rushing back. These are real experiences worth understanding before starting.

What influences individual results, and why reviews alone cannot predict yours

A question our prescribers hear regularly: why did one person lose 20kg and another lose 6kg on the same dose? Review threads ask this constantly. The honest answer is that several biological factors shape the response: starting weight, metabolic health, how consistently the medicine is used, and whether lifestyle changes accompany it. Semaglutide is licensed alongside a reduced-calorie diet and increased physical activity, not instead of them, and reviews from people who made both changes alongside treatment tend to report better outcomes.

Dose also matters more than some reviews suggest. The MHRA approved a 7.2mg maintenance dose for Wegovy in April 2026, and early data from that phase showed around 20.7% average weight loss over 72 weeks, approaching results seen with tirzepatide. If you are comparing Wegovy reviews across time, older accounts from before 7.2mg was available will not reflect what is now possible at higher doses. For a broader picture of how the two medicines compare, the semaglutide treatment page covers the licensed options in more detail.

Reviews of compounded or unlicensed semaglutide products (sometimes found alongside branded Wegovy accounts) are a separate category entirely. Those products are not the same medicine in regulatory terms. For context on what to look for in a legitimate supply, the guidance on obtaining Wegovy safely covers the key points.

Oral semaglutide reviews: a newer picture still forming

Since the MHRA approved Wegovy tablets in June 2026 (the first licensed oral GLP-1 medicine for weight management in the UK) a new wave of user accounts has begun to appear. The trial data (OASIS 4, 64 weeks) showed around 13.6% average weight loss, rising to roughly 17% among participants who stayed fully adherent. The oral formulation requires a specific morning routine: taken on an empty stomach with a small amount of plain water, with at least 30 minutes before food, coffee or other medicines.

Early user reviews reflect two things clearly. First, the tablet removes the injection barrier that keeps some people from starting treatment, and many people mention this as a reason they finally tried semaglutide. Second, the strict morning routine can be harder to sustain than it sounds, and some reviewers note that forgetting or shortening the fasting window seems to affect how settled the medicine feels. If you are curious about how treatment begins at a very low introductory amount, our page on 0.05 ml semaglutide explains what that starting point involves. Reviews of the combination formulations that circulate online are worth reading cautiously, those products differ from the licensed Wegovy tablet.

If you are weighing the injection against the tablet, the treatment overview outlines both licensed options. The right choice depends on individual circumstances, something a prescriber can work through with you. To see whether you meet the eligibility criteria, check your eligibility with our clinical team.